RCMNY
PTGX icon

Rubric Capital Management (New York)’s Protagonist Therapeutics PTGX Stock Holding History

Rubric Capital Management (New York)’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-427,998
Closed -$45.1M – 99
2026
Q1 		$45.1M Buy
+427,998
New +$37.9M 0.48% 44
2024
Q3 		– Sell
-198,059
Closed -$6.86M – 73
2024
Q2 		$6.86M Hold
198,059
– – 0.18% 57
2024
Q1 		$5.73M Buy
+198,059
New +$5.39M 0.17% 62

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Rubric Capital Management (New York)'s PTGX Position: Q2 2026 in Review

Rubric Capital Management (New York) sold out of Protagonist Therapeutics (PTGX) in Q2 2026, closing a stake of 427,998 shares — an estimated $45.1M sold.

Rubric Capital Management (New York) first reported a position in PTGX in Q1 2024 and held it in 3 quarters. The position peaked at $45.1M in Q1 2026. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Rubric Capital Management (New York) reported no remaining Protagonist Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Rubric Capital Management (New York) sold 427,998 Protagonist Therapeutics shares in Q2 2026, an estimated $45.1M.
  • Rubric Capital Management (New York) first reported a position in Protagonist Therapeutics in Q1 2024 and held it in 3 quarters.
  • Rubric Capital Management (New York)'s Protagonist Therapeutics position peaked at $45.1M in Q1 2026.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Rubric Capital Management (New York)'s 13F filing for Q2 2026, filed 14 Aug 2026.